TITLE

FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL

PUB. DATE
October 2003
SOURCE
Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the announcement of Lorus Therapeutics Inc. that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's Investigational New Drug Application to begin a Phase II clinical trial to investigate Lorus' lead antisense drug for breast cancer, as of October 2003.
ACCESSION #
10935539

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;1/14/2011, Vol. 22 Issue 10, p5 

    The article reports that Lorus Therapeutics Inc. has enrolled the first cancer patient in a Phase I study to evaluate its small-molecule anticancer drug candidate LOR-253.

  • R&D Update -- Other Cancers.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p11 

    Reports developments in research and development related to cancer treatment as of February 2003. Approval of the Data Safety Monitoring Board to the continuation of the thymitaq liver cancer trial of Eximias Pharmaceutical Corp.; Expansion of the renal cell carcinoma trial of Lorus Therapeutics...

  • Lorus and BioVectra sign pancreatic cancer drug deal.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p14 

    Reports on the commercial supply agreement between Lorus Therapeutics Inc. and BioVectra DCL company for pancreatic cancer candidate Virulizin. Completion of the technology transfer process to BioVectra; Evaluation on the use of Virulizin as a treatment of advanced pancreatic cancer in...

  • Cyclacel acquires novel anticancer drug from Lorus Therapeutics.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p22 

    Reports on the acquisition of the anticancer drug CYC381 from the biotechnology firm Lorus Therapeutics Inc. by Cyclacel Ltd. Ability of the drug to arrest cancer cells; Terms of the agreement; Payment received by Lorus from the agreement.

  • INDUSTRY UPDATE - Other Cancers.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p14 

    Reports developments related to cancer as of March 2003. Positive opinion received by Novartis AG from European regulators at the Committee for Proprietary Medicinal Products over a label update for its Zometa drug; Patent granted to protect the R1 component of ribonucleotide reductase of Lorus...

  • Lorus to advance its anticancer drug, GTI-2501 into phase II clinical trial.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Announces the plan of Lorus Therapeutics to advance its antisense, anticancer drug, GTI-2501 into a phase II clinical trial for the treatment of advanced metastatic prostate cancer, in the fall of 2003. Mechanism of action of GTI-2501 observed during preclinical investigations.

  • Lorus signs cancer pact with Sumitomo and Koken.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p17 

    Reports that Lorus Therapeutics Inc. has signed a collaboration agreement with Sumitomo Pharmaceuticals Co. and Koken for the development of cancer drug, Thioredoxin. Terms of the agreement; Use of Thioredoxin; Comments of the Lorus CEO, Jim Wright regarding on their collaboration with the...

  • Financings Roundup.  // BioWorld Today;8/16/2011, Vol. 22 Issue 158, p7 

    The article reports that Lorus Therapeutics Inc. of Toronto, Canada completed its offering of 5.5 million units prices at 40Canadian cents apiece for a gross proceeds of 2.2 million Canadian dollars.

  • Lorus Therapeutics announces patent allowance for small molecule drugs.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p15 

    The article reports on the allowance of Lorus Therapeutics Inc.'s first patent in China for novel drug candidates from its small molecule program.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics